WO2007081465A3 - Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation - Google Patents

Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation Download PDF

Info

Publication number
WO2007081465A3
WO2007081465A3 PCT/US2006/046802 US2006046802W WO2007081465A3 WO 2007081465 A3 WO2007081465 A3 WO 2007081465A3 US 2006046802 W US2006046802 W US 2006046802W WO 2007081465 A3 WO2007081465 A3 WO 2007081465A3
Authority
WO
WIPO (PCT)
Prior art keywords
interleukin
antibodies
cell proliferation
induced cell
inhibiting
Prior art date
Application number
PCT/US2006/046802
Other languages
French (fr)
Other versions
WO2007081465A2 (en
Inventor
Ming-Shi Chang
Original Assignee
Chi Mei Medical Ct
Ming-Shi Chang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chi Mei Medical Ct, Ming-Shi Chang filed Critical Chi Mei Medical Ct
Publication of WO2007081465A2 publication Critical patent/WO2007081465A2/en
Publication of WO2007081465A3 publication Critical patent/WO2007081465A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

Antibody to human IL-20 protein, a method for generation thereof and cells producing this antibody are disclosed. The antibody of the present invention has specificity to neutralizing hIL-20W-induced CPAE proliferation activity, and is useful for treating IL- 20-induced inflammation, such as artheriosclerosis and rheumatoid arthritis.
PCT/US2006/046802 2005-12-09 2006-12-07 Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation WO2007081465A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29832905A 2005-12-09 2005-12-09
US11/298,329 2005-12-09

Publications (2)

Publication Number Publication Date
WO2007081465A2 WO2007081465A2 (en) 2007-07-19
WO2007081465A3 true WO2007081465A3 (en) 2008-03-06

Family

ID=38256781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046802 WO2007081465A2 (en) 2005-12-09 2006-12-07 Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation

Country Status (1)

Country Link
WO (1) WO2007081465A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000721A1 (en) 2008-06-30 2010-01-07 Novo Nordisk A/S Anti-human interleukin-20 antibodies
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
AU2013217940A1 (en) 2012-02-10 2014-07-31 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014006230A1 (en) 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSIEH ET AL.: "Interleukin-20 promotes angiogenesis in a direct and indirect manner", GENES AND IMMUNOLOGY, vol. 7, 2006, pages 234 - 242 *
HUNT ET AL.: "Ultraviolet B Light Stimulates Interleukin-20 Expression by Human Epithelial Keratinocytes", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 82, September 2006 (2006-09-01) - October 2006 (2006-10-01), pages 1292 - 1300 *

Also Published As

Publication number Publication date
WO2007081465A2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2007081465A3 (en) Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
MX2011009798A (en) Carrier immunoglobulins and uses thereof.
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
ZA200804346B (en) Anit-Aß globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007065027A3 (en) Carbonic anhydrase ix (g250) antibodies and methods of use thereof
WO2010046775A3 (en) Methods for producing antibodies from plasma cells
UA97946C2 (en) Monoclonal antibody which specifically binds to an extracellular domain of human ilt7
WO2007041171A3 (en) Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
WO2010007533A3 (en) Human cytomegalovirus neutralizing antibodies and use thereof
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
MY183134A (en) Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
WO2006068975A3 (en) Binding proteins specific for human matriptase
MX2009008608A (en) Monoclonal anti-cxcl13 antibodies.
EA201001762A1 (en) ANTIBODIES AND METHODS OF THEIR RECEPTION
WO2012082752A3 (en) Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2012012461A3 (en) Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
ATE370163T1 (en) ANTIBODIES FOR ISOLATION AND/OR IDENTIFICATION OF MESENCHYMAL STEM CELLS AND METHOD FOR ISOLATION AND/OR IDENTIFICATION OF MESENCHYMAL STEM CELLS
WO2007030678A3 (en) Methods of genome-wide location analysis in stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06847524

Country of ref document: EP

Kind code of ref document: A2